Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inspra, an aldosterone antagonist, is employed in cardiovascular conditions that involve excess aldosterone activity. Hypertension: lowers blood pressure by promoting sodium excretion and potassium retention. Heart failure (reduced ejection fraction): improves survival and reduces hospitalizations by decreasing cardiac remodeling. Post‑myocardial infarction: reduces the risk of cardiovascular death and heart failure when added to standard therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Hyponatremia: low sodium concentration. - Dizziness or light‑headedness. - Headache. - Fatigue. - Gastrointestinal discomfort such as nausea.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute kidney injury or worsening renal function. - Allergic reactions including rash, pruritus, or angioedema. - Hormonal disturbances causing menstrual irregularities. - Elevated serum creatinine. - Hepatic enzyme abnormalities.

Before initiating therapy, consider the following precautions. - Monitor serum potassium and renal function regularly, especially in patients with renal impairment. - Avoid use in patients with hyperkalemia or severe renal dysfunction. - Caution in individuals taking other potassium‑sparing agents or supplements. - Adjust dose or discontinue if significant increases in creatinine occur. - Use with caution in the elderly due to altered pharmacokinetics. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Eplerenone may interact with several concomitant medications.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: risk of severe hyperkalemia. - ACE inhibitors or ARBs: additive effect on potassium and renal function. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase eplerenone plasma levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal clearance and increase potassium. - Digoxin: heightened risk of digoxin toxicity with elevated potassium. - Cyclosporine: may potentiate renal impairment. - Thiazide diuretics: can counteract potassium‑sparing effect, requiring monitoring.